Steris had its Relative Strength (RS) Rating upgraded from 69 to 73 Monday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if Steris can continue to rebound and hit that benchmark.
Steris is working on a flat base with a 252.79 entry. See if it can break out in volume at least 40% above average.
While revenue growth fell last quarter from 6% to 4%, earnings-per-share grew 14%, up from 11% in the previous report.
The company earns the No. 6 rank among its peers in the Medical-Systems/Equipment industry group. iRadimed, Brainsway ADR and Masimo are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
